Menu
Recruiting NCT07362160

Clear Orthodontic Expander Versus Hyrax

No phase Interventional Malocclusion Narrow Maxilla

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: New clear expander, Hyrax expander.
Who it may be relevant to
Registry conditions: Malocclusion, Narrow Maxilla. Basic parameters: 10 years — 14 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Iraq
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Evaluating the Clinical Performance of a Novel Clear Orthodontic Expander Versus Hyrax: A Randomized Clinical Trial

Overview

This study will be conducted to evaluate the effectiveness of a clear expander fabricated from 2-mm biocompatible polyethylene terephthalate glycol (PETG) thermoforming material integrated with an expansion screw in achieving dental and skeletal expansion in adolescent patients, compared with the conventional Hyrax expander.

Detailed description

This will be a multicenter randomize clinical trial with two-arm parallel groups, and will be conducted at the Department of Orthodontics, College of Dentistry, University of Baghdad, as well as different specialized dental centers affiliated with the Iraqi Ministry of Health, and some private clinics.

The sample size will be calculated based on previous studies with similar aim to measure the skeletal expansion. A minimum sample size of 17 patients was required, and in order to account for a 15% dropout, a total of 20 patients will be recruited for each group (new clear expander and hyrax expander). The amount of 2.5 mm or greater of maxillary sutural opening will be considered clinically effective.

Two randomizations will be employed, one for the expander type and the other for the cleaning method of the new expander, a computer random generator will be used to develop a simple randomization with an equal allocation ratio (1:1) and without stratification.

Data Collection and Measurements will be include, CBCT evaluation, Intraoral scan of the maxillary arch evaluation, overjet and overbite, CBCT-derived cephalometric images will be used to measure the maxillary mandibular plane angle, Microbial evaluation after using two different methods for cleaning the new clear expander and at the end of the treatment, the patient will be asked to fill out a questionnaire about the treatment, giving information about their experience and satisfaction during treatment.

Data will be analyzed using the Statistical Package for Social Sciences for Windows, version 26.0, including Descriptive Statistics 9numbers, frequencies, percentages, mean, median, and standard deviations), Reliability Statistics (an intraclass correlation coefficient), and Inferential Statistics (Levene's test, Shapiro Wilk test, Paired samples t-test and Independent samples t-test).

Interventions

  • Device New clear expander
    All patients with a clear expander will be instructed to wear the appliance 24 hours a day, except during eating and cleaning. The expander will be activated twice daily (0.2 mm per turn). Patients will be provided with an instruction brochure and advised to use a reminder to ensure compliance. The expansion will continue until the desired amount of the maxillary arch expansion occurs when the maxillary first molars' palatal cusps occlude the lingual side of the mandibular first molar buccal cus
  • Device Hyrax expander
    The activation protocol for the Hyrax expander will be the same in all patients, twice daily (0.2 mm per turn). The expansion will continue until the desired amount of the maxillary arch expansion occurs when the maxillary first molars' palatal cusps occlude the lingual side of the mandibular first molar buccal cusps to overcome the expected relapse due to the elasticity of the palatal soft tissue.

Primary outcome measures

  • CBCT evaluation [Time frame: pre-treatment (T0) and immediately post-treatment (T1) around one to two months]
Secondary outcome measures (5)
  • Intraoral scan of the maxillary arch evaluation [Time frame: pre-treatment (T0) and post-treatment (T1) around one to two months]
  • Clinical evaluation [Time frame: pre-treatment (T0) and immediately post-treatment (T1) around one to two months]
  • Cephalometric analysis [Time frame: pre-treatment (T0) and immediately post-treatment (T1) around one to two months]
  • Microbial evaluation [Time frame: after one month.]
  • Patient satisfaction with the appliance [Time frame: around one to two months]

Eligibility criteria

Inclusion criteria

  • Patients' age at the start of treatment will range from 10-14 years.
  • Unstable unilateral or bilateral posterior crossbite due to maxillary constriction.
  • The first molars are fully erupted.
  • Good oral health free from caries and periodontal problems at the start of treatment.
  • Good general health.

Exclusion criteria

  • Patients with obvious facial asymmetry.
  • Patients with orofacial cleft.
  • Patients with previous orthodontic treatment.
  • Patients with bad oral habits.
  • Patients with active periodontal disease.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Iraq · 1 center
  • University of Baghdad/Collage of Dentistry — Baghdad

Identifiers

NCT: NCT07362160 · 1158425 · 1158

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗